KIF motor properties are currently being explored for therapeutic benefit in cancer clinical trials, including KIF11 inhibitors SB-743921 (Cytokinetics, San Francisco, CA, USA), ARRY-520 (Array BioPharma, Boulder, CO, USA), AZD4877 (AstraZeneca, Cambridge, UK), MK0731 (Merck & Co., Kenilworth, NJ, USA), Litronesib (Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan and Eli Lilly & Co., Indianapolis, IN, USA), ARQ 621 (ArQule Inc, Burlington, VT, USA), and 4SC-205 (4SC AG, Martinsried, Germany) [46]. The gene discussed is KIF11; the disease is cancer.